Abstract
Background and purpose Esophageal cancer has the seventh highest incidence and sixth highest fatality rate of all malignant tumors. It’s a type of cancer that has a greater fatality rate than morbidity. In the treatment of advanced esophageal and squamous cell carcinoma, targeted and immune checkpoint inhibitors have showed promising outcomes in recent years. The aim of this research was to examine the effectiveness and safety of immune checkpoint inhibitors in combination with antiangiogenic medicines in the treatment of unresectable patients with locally progressed / distant metastatic esophageal squamous cell carcinoma.
Methods Before April 15, 2022, randomized controlled trials of immune checkpoint inhibitors combined with anti-angiogenic drugs in the treatment of esophageal cancer will be searched on PubMed, Cochrane Library, EMBASE, WebofScience, China Knowledge Network, Wanfang Data Knowledge Service Platform, and VIP. The two authors independently extracted the data, checked the data, and used the “bias risk” tool in the Cochrane intervention system evaluation manual to independently evaluate the bias included in the study. When the extracted data were similar enough, the Revman5.4 software was used for meta analysis. If the summary data could not be collected for meta analysis, the results would be summarized in a narrative way.
Discussion This paper introduces in detail the systematic review and design method of immune checkpoint inhibitors mixture with antiangiogenic drugs in the treatment of unresectable locally advanced / distant metastatic esophageal squamous cell carcinoma.
Systematic review registration The review protocol has been registered in PROSPERO CRD42022324666
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Henan Provincial Administration of Traditional Chinese Medicine, Henan Provincial Traditional Chinese Medicine Scientific Research Special Project,2022ZY1089(20000)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author: Juanjuan Lu, female, postgraduate student, Henan University of Traditional Chinese Medicine (Second Clinical Medical College), 17739221512{at}qq.com, 1123516147{at}qq.com.
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- EC
- Esophageal cancer
- ESCC
- Esophageals squamous cell carcinoma
- ICI
- Immune checkpoint inhibitors
- PD-1
- Programmed cell death-1 receptor
- PFS
- Progression-free survival
- OS
- Overall survival
- ORR
- Objective remission rate
- PRISMA-P
- Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
- CNKI
- China National Knowledge Internet
- HR
- Hazard ratio
- CI
- Confidence interval
- RR
- Relative risk
- MD
- Mean difference
- SMD
- Standardized mean difference